Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.08 USD
Change Today +0.37 / 6.48%
Volume 873.9K
IG On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:04 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

igi laboratories inc (IG) Snapshot

Open
$5.65
Previous Close
$5.71
Day High
$6.11
Day Low
$5.56
52 Week High
03/2/15 - $12.05
52 Week Low
05/1/15 - $4.75
Market Cap
321.4M
Average Volume 10 Days
771.4K
EPS TTM
$-0.02
Shares Outstanding
52.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IGI LABORATORIES INC (IG)

Related News

No related news articles were found.

igi laboratories inc (IG) Related Businessweek News

No Related Businessweek News Found

igi laboratories inc (IG) Details

IGI Laboratories, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets topical formulations in the United States. It sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms under IGI label. The company also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter (OTC) and cosmetic markets. Its products are used in various applications from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, the company offers pharmaceutical contract services comprising formulating, testing, and/or manufacturing prescription drugs and medical devices; and contract development services consisting of developing topical formulations. It has a license agreement with Novavax, Inc. to utilize the Novasome lipid vesicle encapsulation and certain other technologies for applications in animal pharmaceuticals, biologicals, and other animal health products; foods, food applications, nutrients, and flavorings; cosmetics, consumer products, and dermatological OTC and prescription products; fragrances; and chemicals, including herbicides, insecticides, pesticides, paints and coatings, photographic chemicals, and other specialty chemicals. The company was formerly known as IGI, Inc. and changed its name to IGI Laboratories, Inc. in May 2008. IGI Laboratories, Inc. was founded in 1977 and is based in Buena, New Jersey.

81 Employees
Last Reported Date: 03/16/15
Founded in 1977

igi laboratories inc (IG) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $713.6K
Chief Financial Officer and Secretary
Total Annual Compensation: $331.3K
Compensation as of Fiscal Year 2014.

igi laboratories inc (IG) Key Developments

IGI Laboratories, Inc. Provides Earnings Guidance for the Second Quarter Ending June 30, 2015 and Year Ending December 31, 2015

IGI Laboratories, Inc. provided earnings guidance for the second quarter ending June 30, 2015 and year ending December 31, 2015. Total revenues for the three months ended June 30, 2015 are still expected to be between $7.0 and $8.0 million. Due to the effect of a price decline in one product in the second quarter of 2015, the company expects gross margin in the second quarter to approximate 34% to 35%. The company expects sequential improvement quarter over quarter in total revenue for the remainder of the year, and therefore expects total revenue between $35.0 and $40.0 million for the year ended December 31, 2015. The company anticipates sequential improvement in gross margin quarter over quarter for the remainder of the year, and therefore expects gross margin of 43% to 50% for the year ended December 31, 2015.

IGI Laboratories, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 09:20 AM

IGI Laboratories, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 09:20 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Jason Grenfell-Gardner, Chief Executive Officer, President and Director, Jenniffer L. Collins, Chief Financial Officer and Secretary.

IGI Laboratories Announces Second ANDA Submission of 2015

IGI Laboratories, Inc. announced it has submitted its second abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA) of 2015, which brings the Company's total number of ANDA submissions now pending at the FDA to twenty-four.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IG:US $6.08 USD +0.37

IG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $43.96 USD +1.12
Mylan NV $72.04 USD +1.49
Taro Pharmaceutical Industries Ltd $151.00 USD +12.44
View Industry Companies
 

Industry Analysis

IG

Industry Average

Valuation IG Industry Range
Price/Earnings 34.7x
Price/Sales 8.2x
Price/Book 6.7x
Price/Cash Flow 26.6x
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IGI LABORATORIES INC, please visit www.igilabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.